Invesco’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $18.6M | Sell |
752,839
-540,639
| -42% | -$12.9M | ﹤0.01% | 1484 |
|
|
2025
Q4 | $30.2M | Buy |
1,293,478
+60,221
| +5% | +$1.34M | ﹤0.01% | 1269 |
|
|
2025
Q3 | $24.3M | Buy |
1,233,257
+19,557
| +2% | +$402K | ﹤0.01% | 1372 |
|
|
2025
Q2 | $26.3M | Buy |
1,213,700
+14,073
| +1% | +$332K | ﹤0.01% | 1307 |
|
|
2025
Q1 | $29.1M | Buy |
1,199,627
+352,776
| +42% | +$7.94M | 0.01% | 1261 |
|
|
2024
Q4 | $17.7M | Sell |
846,851
-92,675
| -10% | -$1.99M | ﹤0.01% | 1554 |
|
|
2024
Q3 | $18.7M | Buy |
939,526
+100,071
| +12% | +$1.86M | ﹤0.01% | 1495 |
|
|
2024
Q2 | $13M | Sell |
839,455
-154,603
| -16% | -$2.41M | ﹤0.01% | 1653 |
|
|
2024
Q1 | $15.8M | Buy |
994,058
+74,411
| +8% | +$1.12M | ﹤0.01% | 1562 |
|
|
2023
Q4 | $15.5M | Sell |
919,647
-107,954
| -11% | -$1.48M | ﹤0.01% | 1555 |
|
|
2023
Q3 | $12M | Sell |
1,027,601
-197,013
| -16% | -$2.64M | ﹤0.01% | 1637 |
|
|
2023
Q2 | $16.5M | Buy |
1,224,614
+89,766
| +8% | +$1.29M | ﹤0.01% | 1472 |
|
|
2023
Q1 | $18.8M | Sell |
1,134,848
-303,353
| -21% | -$5M | 0.01% | 1385 |
|
|
2022
Q4 | $26.8M | Sell |
1,438,201
-42,708
| -3% | -$658K | 0.01% | 1224 |
|
|
2022
Q3 | $19M | Buy |
1,480,909
+527,647
| +55% | +$6.25M | 0.01% | 1349 |
|
|
2022
Q2 | $6.68M | Buy |
953,262
+479,765
| +101% | +$3.52M | ﹤0.01% | 2122 |
|
|
2022
Q1 | $3.92M | Buy |
473,497
+437,247
| +1,206% | +$3.09M | ﹤0.01% | 2493 |
|
|
2021
Q4 | $245K | Sell |
36,250
-3,231
| -8% | -$21.2K | ﹤0.01% | 3703 |
|
|
2021
Q3 | $209K | Buy |
39,481
+5,119
| +15% | +$28K | ﹤0.01% | 3783 |
|
|
2021
Q2 | $198K | Buy |
34,362
+3,257
| +10% | +$16.8K | ﹤0.01% | 3792 |
|
|
2021
Q1 | $143K | Sell |
31,105
-4,515
| -13% | -$17.9K | ﹤0.01% | 3716 |
|
|
2020
Q4 | $119K | Buy |
35,620
+7,304
| +26% | +$24.5K | ﹤0.01% | 3617 |
|
|
2020
Q3 | $84K | Sell |
28,316
-13,594
| -32% | -$53.2K | ﹤0.01% | 3582 |
|
|
2020
Q2 | $194K | Buy |
41,910
+12,926
| +45% | +$58.1K | ﹤0.01% | 3482 |
|
|
2020
Q1 | $111K | Buy |
28,984
+8,311
| +40% | +$34.1K | ﹤0.01% | 3551 |
|
|
2019
Q4 | $77K | Sell |
20,673
-373,673
| -95% | -$1.75M | ﹤0.01% | 3619 |
|
|
2019
Q3 | $2.09M | Buy |
+394,346
| New | +$2.1M | ﹤0.01% | 2610 |
|
|
2019
Q1 | – | Sell |
-25,652
| Closed | -$49K | – | 3724 |
|
|
2018
Q4 | $49K | Sell |
25,652
-946
| -4% | -$2.71K | ﹤0.01% | 3693 |
|
|
2018
Q3 | $101K | Sell |
26,598
-1,960
| -7% | -$6.14K | ﹤0.01% | 3785 |
|
|
2018
Q2 | $89K | Buy |
+28,558
| New | +$86.6K | ﹤0.01% | 3783 |
|
|
2016
Q1 | – | Sell |
-413,770
| Closed | -$1.01M | – | 3712 |
|
|
2015
Q4 | $1.01M | Buy |
413,770
+1,017
| +0.2% | +$2.91K | ﹤0.01% | 2933 |
|
|
2015
Q3 | $1.24M | Buy |
412,753
+411,371
| +29,766% | +$1.78M | ﹤0.01% | 2793 |
|
|
2015
Q2 | $6K | Buy |
+1,382
| New | +$5.51K | ﹤0.01% | 4110 |
|
|
2014
Q3 | – | Sell |
-67,393
| Closed | -$171K | – | 4102 |
|
|
2014
Q2 | $171K | Buy |
+67,393
| New | +$144K | ﹤0.01% | 3766 |
|
Other funds holding CPRX
VCM
DM
VPM
Invesco's CPRX Position: Q1 2026 in Review
Invesco reduced its Catalyst Pharmaceutical (CPRX) stake by 42% in Q1 2026, selling an estimated $12.9M and leaving 752,839 shares worth $18.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1484.
Invesco first reported a position in CPRX in Q2 2014 and has held it in 34 quarters since. The position peaked at $30.2M in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Invesco held 752,839 shares of Catalyst Pharmaceutical worth $18.6M as of Q1 2026.
- Invesco sold 540,639 Catalyst Pharmaceutical shares in Q1 2026, an estimated $12.9M.
- Catalyst Pharmaceutical made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1484 holding.
- Invesco first reported a position in Catalyst Pharmaceutical in Q2 2014 and has held it in 34 quarters since.
- Invesco's Catalyst Pharmaceutical position peaked at $30.2M in Q4 2025.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.